炎性肠病肠道微生态改变及益生菌的治疗价值

被引:18
作者
杨桦
杜广胜
机构
[1] 第三军医大学附属新桥医院普通外科
关键词
D O I
暂无
中图分类号
R574 [肠疾病];
学科分类号
100201 [内科学];
摘要
<正>炎性肠病(inflammatory bowel disease,IBD)是一类反复发作的慢性炎性肠道病变,主要包括溃疡性结肠炎(ulcerative colitis,UC)和克罗恩病(Crohn disease,CD)。目前,对炎性肠病的治疗主要集中于减轻炎性反应的急性发作而不能做到根治,原因主要是炎性肠病的病因和发病机制尚未完全明确。根据流行病学统计,IBD发病主要与社会的发达程度(发达国家发病率高)、经济环境(城市较农村发病率高)、饮食因素(缺乏母乳喂养、高蔗糖及动物脂肪摄人
引用
收藏
相关论文
共 8 条
[1]
Analysis of bacterial bowel communities of IBD patients: What has it revealed? [J].
Sokol, Harry ;
Lay, Christophe ;
Seksik, Philippe ;
Tannock, Gerald W. .
INFLAMMATORY BOWEL DISEASES, 2008, 14 (06) :858-867
[2]
Probiotics and prebiotics in inflammatory bowel disease: microflora 'on the scope' [J].
Damaskos, Dimitrios ;
Kolios, George .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2008, 65 (04) :453-467
[3]
Specificities of the fecal microbiota in inflammatory bowel disease [J].
Sokol, H ;
Seksik, P ;
Rigottier-Gois, L ;
Lay, C ;
Lepage, P ;
Podglajen, I ;
Marteau, P ;
Doré, J .
INFLAMMATORY BOWEL DISEASES, 2006, 12 (02) :106-111
[4]
Saccharomyces boulardii inhibits inflammatory bowel disease by trapping T cells in mesenteric lymph nodes [J].
Dalmasso, Guillaume ;
Cottrez, Francoise ;
Imbert, Veronique ;
Lagadec, Patricia ;
Peyron, Jean-Francois ;
Rampal, Patrick ;
Czerucka, Dorota ;
Groux, Herve .
GASTROENTEROLOGY, 2006, 131 (06) :1812-1825
[5]
Saccharomyces boulardii produces a soluble anti-inflammatory factor that inhibits NF-κB-mediated IL-8 gene expression.[J].Stavros Sougioultzis;Simos Simeonidis;K. Ramakrishnan Bhaskar;Xinhua Chen;Pauline M. Anton;Sarah Keates;Charalabos Pothoulakis;Ciarán P. Kelly.Biochemical and Biophysical Research Communications.2006, 1
[6]
A pilot trial of Saccharomyces boulardii in ulcerative colitis [J].
Guslandi, M ;
Giollo, P ;
Testoni, PA .
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2003, 15 (06) :697-698
[7]
Saccharomyces boulardii in maintenance treatment of Crohn's disease [J].
Guslandi, M ;
Mezzi, G ;
Sorghi, M ;
Testoni, PA .
DIGESTIVE DISEASES AND SCIENCES, 2000, 45 (07) :1462-1464
[8]
Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis:: a randomised trial [J].
Rembacken, BJ ;
Snelling, AM ;
Hawkey, PM ;
Chalmers, DM ;
Axon, ATR .
LANCET, 1999, 354 (9179) :635-639